Potential of novel drug delivery strategies for the treatment of hyperlipidemia

References

• Gupta A, Sehgal V, Mehan S. Hyperlipidemia: an updated review. Int J Biopharm Toxicol Res 2011;1:81–9.
   Google Scholar
• Rohilla A, Dagar N, Rohilla S, et al. Hyperlipidemia – a deadly pathological condition. Int J Curr Pharmaceut Res 2012;4:15–18.
   Google Scholar
• Toth PP. High density lipoprotein: epidemiology, metabolism and antiatherogenic effects. Dis Mon 2001;47:369–99.
   PubMed Web of Science ®Google Scholar
• Bhatnagar D, Soran H, Durrington PN, et al. Management. Br Med J 2008;337:993.
   PubMed Web of Science ®Google Scholar
• Dog TL, Riley D. Management of hyperlipidaemia. Alternative Ther 2003;9:28–40.
   PubMedGoogle Scholar
• Jehle AJ. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (ATP III Final Report). J Am Med Assoc 2002;285:2486–97.
   Web of Science ®Google Scholar
• Libby P. The vascular biology of atherosclerosis. In: Braunwald E, Bonow RO, eds. Braunwald's heart disease: a textbook of cardiovascular medicine. 9th ed. Philadelphia, PA: Saunders Elsevier; 2011:43.
   Google Scholar
• Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. Can Med Assoc J 2007;176:1113–20.
   PubMed Web of Science ®Google Scholar
• Global Health Observatory data. World health organization (WHO) updates. 2015. Available from: http://www.who.int/gho/ncd/risk_factors/cholesterol_text/en/ [last accessed 12 Sep 2015].
   Google Scholar
• Center of Disease Control and Prevention. National center for health statistics. United States 2014. Available from: http://www.cdc.gov/nchs/fastats/cholesterol.htm [last accessed 16 Oct 2015].
   Google Scholar
• World Health Organization. Non communicable Diseases (NCD) Country Profiles, 2014. Available from: http://apps.who.int/iris/bitstream/10665/128038/1/9789241507509_eng.pdf [last accessed 14 Apr 2016].
   Google Scholar
• Global Health Observatory data. World health organization (WHO) updates. 2015. Available from: http://www.who.int/chp/chronic_disease_report/en/ [last accessed 12 Sep 2015].
   Google Scholar
• Joshi SR, Anjana RM, Deepa M, et al. Prevalence of Dyslipidemia in Urban and Rural India: the ICMR–INDIAB study PLoS One 2014;9:e96808.
   PubMed Web of Science ®Google Scholar
• Dipiro TJ. Pharmacotherapy: a pathophysiological approach. 6th ed. New York: The Mc Graw Hill Companies Inc; 2008:435.
   Google Scholar
• Grundy SM. Pathogenesis of hyperlipoproteinemia. J Lipid Res 1984;25:1611–1618.
   PubMed Web of Science ®Google Scholar
• Talbert RL. Pharmacotherapy, a pathophysiologic approach. 4th ed. Stamford: Appleton & Lange; 1999:350–73.
   Google Scholar
• Havel RJ, Rapaport E. Management of primary hyperlipidemia. New Engl J Med 1995;332:1491–8.
   PubMed Web of Science ®Google Scholar
• Jain KS, Kathiravan MK, Somani RS, Shishoo CJ. The biology and chemistry of hyperlipidemia. Bioorg Med Chem 2007;15:4674–99.
   PubMed Web of Science ®Google Scholar
• Srinivasa Rao K, Prasad T, Mohanta GP, Manna PK. An overview of statins as hypolipidemic drugs. Int J Pharmaceut Sci Drug Res 2011;3:178–83.
   Google Scholar
• Mckenney JM. Pharmacologic characteristics of statins. Clin Cardiol 2003;26:32–8.
   Web of Science ®Google Scholar
• Lim S, Sakuma I, Quon MJ, Koh KK. Differential metabolic actions of specific statins: clinical and therapeutic considerations. Antioxidant Redox Signal 2014;20:1286–99.
   PubMed Web of Science ®Google Scholar
• Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995;31:9–27.
   PubMed Web of Science ®Google Scholar
• Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413–28.
   PubMed Web of Science ®Google Scholar
• Kajinami K, Mabuchi H, Saito Y. NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin Investig Drugs 2000;9:2653–61.
   PubMed Web of Science ®Google Scholar
• Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996;36:604–9.
   PubMed Web of Science ®Google Scholar
• Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, Rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002;54:472–7.
   PubMed Web of Science ®Google Scholar
• Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther 2002;24:2022–50.
   PubMed Web of Science ®Google Scholar
• Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995;52:1639–45.
   PubMed Web of Science ®Google Scholar
• Radulovic LL, Cilla DD, Posvar EL, et al. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 1995;35:990–4.
   PubMed Web of Science ®Google Scholar
• Smith HT, Jokubaitis LA, Troendle AJ, et al. Pharmacokinetics of Fluvastatin and specific drug interactions. Am J Hypertens 1993;6:375S–82S.
   PubMed Web of Science ®Google Scholar
• Pan HY, DeVault AR, Brescia D. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 1993;31:291–4.
   PubMed Web of Science ®Google Scholar
• Davidson MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs 2002;11:125–41.
   Web of Science ®Google Scholar
• Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism – monograph for physicians. Arch Intern Med 2000;160:2273–80.
   PubMed Web of Science ®Google Scholar
• Ling H, Luoma JT, Hilleman D. A Review of currently available fenofibrate and fenofibric acid formulations. Cardiol Res 2013;4:47–55.
   PubMedGoogle Scholar
• Schachter M. Statins, drug interactions and cytochrome P450. Br J Cardiol 2001;8:311–17.
   Google Scholar
• Sica DA, Gehr TW. Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol 2002;11:48–55.
   PubMedGoogle Scholar
• Muscari A, Puddu GM, Puddu P. Lipid-lowering drugs: are adverse effects predictable and reversible. Cardiology 2002;97:115–21.
   PubMed Web of Science ®Google Scholar
• Knopp RH. Drug treatment of lipid disorders. New Engl J Med 1999;341:498–511.
   PubMed Web of Science ®Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207–13.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373–418.
   PubMed Web of Science ®Google Scholar
• Drugs, medicine database food. 1906. Available from: http://www.drugbank.ca/drugs/db00227 [last accessed 7 Oct 2015].
   Google Scholar
• Sherif S, Niamh H. The ugly side of statins. Systemic appraisal of the contemporary un-known. Open J Endocr Metab Dis 2013;3:179–85.
   Google Scholar
• Staels B, Dallongeville J, Auwerx J, Schoonjans K. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088–93.
   PubMed Web of Science ®Google Scholar
• Hamilton CI, Karam K, David C, Stan W. Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag 2010;6:1023–37.
   PubMedGoogle Scholar
• Tamargo J, Caballero R, Gómez R, et al. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacol Ther 2007;114:107–26.
   PubMed Web of Science ®Google Scholar
• Papadakis JA, Ganotakis ES, Jagroop IA, et al. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 1999;69:237–44.
   PubMed Web of Science ®Google Scholar
• Halpern MJ. Lipids and atherosclerosis. Mol Aspect Med 1995;16:509–710.
   PubMed Web of Science ®Google Scholar
• Obata T. Protective effect of fluvastatin, an inhibitor of 3-Hydroxy-3-methylglutaryl coenzyme A reductase on copper-induced hydroxyl radical generation in the rat heart. Toxicology 2006;223:175–80.
   PubMed Web of Science ®Google Scholar
• Moon YS, Chun P, Chung S. Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia. Drugs Today 2007;43:35–45.
   PubMed Web of Science ®Google Scholar
• Last AL, Ference JD, Falleroni J. Pharmacologic treatment of hyperlipidemia. Am Fam Physician 2011;84:551–8.
   PubMed Web of Science ®Google Scholar
• Henley E, Chang L, Hollander S. Treatment of hyperlipidemia. J Fam Pract 2002;51:370–6.
   PubMed Web of Science ®Google Scholar
• Shah AF, Saini V, Singh R, Kaur K. Application of novel drug delivery system in the pharmacotherapy of hyperlipidemia. J Chem Pharmaceut Sci 2013;6:138–46.
   Google Scholar
• Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery – a review. Pharmaceut Sci Technol Today 2000;3:138–45.
   PubMedGoogle Scholar
• Sampath Kumar KP, Bhowmik D, Dutta A, et al. Recent trends in scope and opportunities of controlled release oral drug delivery systems. Crit Rev Pharmaceut Sci 2012;1:20–33.
   Google Scholar
• Park K. Controlled drug delivery systems: past forward and future back. J Contr Release 2014;190:3–8.
   PubMed Web of Science ®Google Scholar
• Paras C, Hussain MM, Rosenson RS. Emerging Drugs for Hyperlipidemia. Expert Opin Emerg Drugs 2010;15:433–51.
   PubMed Web of Science ®Google Scholar
• Soni GC, Prajapati SK, Chaudhari N. Self nanoemulsion: advance form of drug delivery system. World J Pharm Pharmaceut Sci 2014;3:410–36.
   Google Scholar
• Agrawal S, Giri TK, Tripathi DK, et al. A review on novel therapeutic strategies for the enhancement of solubility for hydrophobic drugs through lipid and surfactant based self-micro emulsifying drug delivery system: a novel approach. Am J Drug Dis Develop 2012;2:143–83.
   Google Scholar
• Deokate UA, Shinde N, Bhingare U. Novel approaches for development and characterization of SMEDDS: review. Int J Curr Pharmaceut Res 2013;5:5–12.
   Google Scholar
• Mokale V, Naik J, Wani D, et al. Preparation and in-vitro characterisation of Lovastatin liquisolid self-emulsified drug delivery system. Int J Chem Environ Biol Sci 2014;2:17–23.
   Google Scholar
• Goyal U, Arora R, Aggarwal G. Formulation, design and evaluation of a self-microemulsifying drug delivery system of lovastatin. Acta Pharm 2012;62:357–70.
   PubMed Web of Science ®Google Scholar
• Patela MJ, Patela NM, Patel RB, Patel RP. Formulation and evaluation of self-microemulsifying drug delivery system of lovastatin. Asian J Pharmaceut Sci 2010;5:266–75.
   Google Scholar
• Kulkarni NS, Ranpise NS, Mohan G. Development and evaluation of solid self nano-emulsifying formulation of rosuvastatin calcium for improved bioavailability. Trop J Pharmaceut Res 2015;14:575–82.
   Web of Science ®Google Scholar
• Patel AR, Vavia PR. Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J 2007;9:E344–52.
   PubMed Web of Science ®Google Scholar
• Ali S, Kolter K. Tackling the challenges with poorly soluble drugs. J Anal Pharmaceut Res 2015;1:1–4.
   Web of Science ®Google Scholar
• Zakia B, Zhang S, Zhang W, Wang J. Formulation development and bioavailability evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) of atorvastatin calcium. Int J Pharmaceut 2013;29:1103–13.
   Google Scholar
• Ladan AN, Singh G, Singh G, Kahkeshan KF. Solid dispersion: methods and polymers to increase the solubility of poorly soluble drugs. J Appl Pharmaceut Sci 2012;2:170–5.
   Google Scholar
• Bhise SD. Ternary solid dispersions of fenofibrate with poloxamer 188 and TPGS for enhancement of solubility and bioavailability. Int J Res Pharmaceut Biomed Sci 2011;2:583–95.
   Google Scholar
• Rao MRP, Gabhe N, Gunjal M, et al. Binary and ternary solid dispersions of fenofibrate for solubility enhancement. Int J Pharm Pharmaceut Sci 2012;4:511–17.
   Google Scholar
• Parmar KR, Shah SR, Sheth NR. Studies in dissolution enhancement of ezetimibe by solid dispersions in combination with a surface adsorbent. Dissolut Technol 2011;18:55–61.
   Web of Science ®Google Scholar
• Choudharya A, Ranaa AC, Aggarwal G, et al. Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability. Acta Pharm Sin B 2012;2:421–8.
   Google Scholar
• Wang Y, Zheng Y, Zhang L, et al. Stability of nanosuspensions in drug delivery. J Control Release 2013;172:1126–41.
   PubMed Web of Science ®Google Scholar
• Malakar J, Basu A, Ghosh A. Nanosuspension: a nano-heterogeneous carrier for drug delivery system. Int J of Pharmaceut Biol Arch 2012;3:4–13.
   Google Scholar
• Mishra S, Panda DS, Pradhan M, et al. Preparation and evaluation of ezetimibe nanosuspension. J Adv Pharmaceut Res 2011;2:185–9.
   Google Scholar
• Athul PV. Preparation characterization of simvastatin nanosuspension by homogenization method. Int J Pharm Tech Res 2013;5:193–7.
   Google Scholar
• Athul PV, Kumar K. Evaluation of hypolipidemic activity of simvastatin nanosuspension in triton WR-1339 induced hyperlipidemic rats. Int J PharmTech Res 2014;6:276–9.
   Google Scholar
• Srikanth MV, Sunil SA, Rao NS, et al. Ion-exchange resins as controlled drug delivery carriers. J Sci Res 2010;2:597–611.
   Google Scholar
• Pande SV, Shirsagar MDV, Chandewar AV. Ion exchange resins pharmaceutical applications and recent advancement. Int J Adv Pharmaceut Sci 2011;2:8–16.
   Google Scholar
• Subramanian S, Singireddy A, Krishnamoorthy K, Rajappan M. Nanosponges: a novel class of drug delivery system – review. J Pharm Pharm Sci 2012;15:103–11.
   PubMed Web of Science ®Google Scholar
• Sharma R, Pathak K. Polymeric nanosponges as an alternative carrier for improved retention of econazole nitrate onto the skin through topical hydrogel formulation. Pharm Dev Technol 2011;16:367–76.
   PubMed Web of Science ®Google Scholar
• Deshpande A, Patel P. Preparation evaluation of cyclodextrin based atorvastatin nanosponges. Am J Pharm Tech Res 2014;4:569–88.
   Google Scholar
• Gupta SK, Singhvi IJ, Shirsat M, et al. Buccal adhesive drug delivery system: a review. Asian J Biochem Pharmaceut Res 2011;2:105–14.
   Google Scholar
• Doijad RC, Sompur CK, Goje AJ, et al. Development and characterization of lovastatin controlled release buccoadhesive dosage form. Int J Pharm Biosci 2011;2:133–40.
   Google Scholar
• Gade R, Aynampudi A, Makineni A, et al. Design and development of pravastatin sodium fast dissolving films from natural mucilage of ocimum bacilicum seeds. Int J Pharm Res Rev 2014;3:17–27.
   Google Scholar
• Yashvant AC, Chaudhari KP, Jadhao UT, et al. Formulation and in-vitro evaluation of simvastatin buccoadhesive tablets. Asian J Pharmaceut Sci Technol 2014;4:156–63.
   Google Scholar
• Mayavanshi AV, Gajjar SS. Floating drug delivery systems to increase gastric retention of drugs: a review. Res J Pharm Technol 2008;1:345–8.
   Google Scholar
• Umamaheshwari RB, Jain S, Jain NK. A new approach in gastroretentive drug delivery system using cholestyramine. Drug Deliv 2003;10:151–60.
   PubMed Web of Science ®Google Scholar
• Danki LS, Sayeed A, Salger S. Design and in-vitro evaluation of gastric floating drug delivery systems of fenofibrate. Int J Pharm BioSci 2010;1:1–27.
   Google Scholar
• Kapoor D, Patel M, Vyas RB, et al. Stomach specific gastroretentive floating tablet of anti-hyperlipidemic drug: formulation development and in-vitro characterization. World J Pharm Pharmaceut Sci 2013;3:607–23.
   Google Scholar
• Asija R, Patel J, Asija SA, et al. Sustained released drug technology: a review. Int J Res Pharm Sci 2012;2:1–13.
   Google Scholar
• Rasve G, Borade G, Deshmukh S, Tagalpallewar A. Pulsatile drug delivery system: current scenario. Int J Pharm Biosci 2011;2:332–43.
   Google Scholar
• Parmar RD, Parikh RK, Vidyasagar G, et al. Pulsatile drug delivery system: an overview. Int J Pharmaceut Sci Nanotech 2009;2:605–14.
   Google Scholar
• Sukanya M, Sai KV. Design development of chronopharmaceutical drug delivery of simvastatin. J Chem Pharmaceut Res 2012;4:3195–200.
   Google Scholar
• Seth N, Gill NS Sharma SD, et al. Development and evaluation of chronotherapeutic system of pravastatin sodium. Int J Univ Pharm Biosci 2014;3:261–9.
   Google Scholar
• Oishi K, Uchida D, Ishida N. Circadian expression of FGF21 is induced by PPARa activation in the mouse liver. FEBS Lett 2008;582:3639–42.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008;83:761–9.
   PubMed Web of Science ®Google Scholar
• Kurakula M, El-Helw AM, Sobahi TR, Abdelaal MY. Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy. Int J Nanomed 2015;10:321–34.
   PubMed Web of Science ®Google Scholar
• Garse H, Jagtap P, Dand N, Kadam V. Studies on lipid nanoparticle formulation of antihyperlipidemic drug. World J Pharmaceut Sci 2015;3:438–47.
   Google Scholar
• Maximov VD, Reukov VV, Barry JN, et al. Protein–nanoparticle conjugates as potential therapeutic agents for the treatment of hyperlipidemia. Nanotechnology 2010;21:1–9.
   Web of Science ®Google Scholar
• Chime SA, Kenechukwu FC, Attama AA. Nanoemulsions — advances in formulation, characterization and applications in drug delivery. In: Sezer AD, ed. Application of nanotechnology in drug delivery. European Union: InTech; 2014:77–126.
   Google Scholar
• Reddy AKB, Debnath S, Babu NM, et al. Design development and evaluation of novel nanoemulsion of simvastatin. Int J Adv Pharmaceut 2013;3:94–101.
   Google Scholar
• Zawilska JB, Wojcieszak J, Olejniczak AB. Prodrugs: a challenge for the drug development. Pharmacol Rep 2013;65:1–14.
   PubMed Web of Science ®Google Scholar
• Registration under the Securities act of 193, Metabasis Therapeutics, Inc. United States Securities and Exchange Commission. Washington DC; 2008. Available from: http://www.sec.gov/Archives/edgar/data/1053221/000110465908031891/a08-13865_1s3.htm [last accessed 16 Oct 2015].
   Google Scholar